A new analysis presented at the European Congress on Obesity suggests that once-daily oral orforglipron may help older adults preserve weight loss and improve blood sugar control after treatment with injectable incretin medicines. The findings, reported by researchers at UTHealth Houston and reviewed in coverage published by News-Medical, add to growing interest in oral options for obesity care as clinicians look for treatments that may be easier to continue over time.
What the analysis found
The post-hoc analysis focused on participants aged 65 years and over who had obesity, with or without type 2 diabetes, and examined results from the ATTAIN clinical trial programme. According to the report, the global ATTAIN-1 and ATTAIN-2 trials evaluated once-daily oral orforglipron 6 mg, 12 mg, or 36 mg versus placebo as an adjunct to healthy diet and physical activity in participants from 9 and 10 countries, respectively. The new analysis found that results and safety profile in older adults were similar to those seen in the broader trial population.
The report also notes that, after major weight loss with injectable incretin therapies, oral orforglipron helped participants preserve much of their progress, which could make it a potential maintenance option for people stopping injections. The analysis was presented at ECO 2026, held in Istanbul, Turkey, from 12-15 May.
Why the findings matter for nutrition and weight management
For diet and nutrition specialists, the interest is not only in weight reduction itself, but in whether patients can sustain progress alongside healthier eating and physical activity. The trial framework described in the report placed orforglipron alongside lifestyle measures rather than instead of them, reflecting a common approach in obesity care. In older adults, where treatment choices can be shaped by tolerability and practicality, a once-daily oral option may be especially relevant.
The report says limited clinical data exist on incretin-based obesity medicines in older adults with or without type 2 diabetes, and that this gap may make some patients and providers cautious. That makes the new subgroup analysis notable, although it remains an early look rather than a final answer on long-term use.
What comes next
The findings will need to be interpreted in the context of the broader trial programme and, ideally, confirmed in additional studies focused specifically on older patients. Still, the analysis adds another piece to the evolving obesity treatment landscape, where nutrition, physical activity and medication are increasingly being considered together rather than as separate tools.
As interest grows in maintenance therapies that can support long-term weight control, the key question will be whether oral options can deliver benefits that are both effective and practical in everyday care.
